Prostate Cancer Clinical Trial
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)
Summary
A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA) 7.3 (18F) Positron Emission Tomography (PET) ligand in men with newly diagnosed prostate cancer.
Eligibility Criteria
Inclusion Criteria:
Patient is male and aged >18 years old.
Histologically confirmed adenocarcinoma of the prostate.
Patients electing to undergo Radical Prostatectomy (RP) with Pelvic lymph node dissection (PLND).
Exclusion Criteria:
Patients who are planned to have an x-ray contrast agent or other PET radiotracer <24 hours prior to the PET scan.
Patients currently receiving, or with a prior history of, Androgen Deprivation Therapy (ADT).
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 34 Locations for this study
Birmingham Alabama, 35233, United States
Los Angeles California, 90048, United States
Orange California, 92868, United States
Santa Monica California, 90403, United States
Atlanta Georgia, 30322, United States
Austell Georgia, 30342, United States
Evanston Illinois, 60201, United States
Maywood Illinois, 60153, United States
Indianapolis Indiana, 46278, United States
Baltimore Maryland, 21287, United States
Towson Maryland, 21204, United States
Boston Massachusetts, 02115, United States
Ann Arbor Michigan, 48109, United States
Detroit Michigan, 48201, United States
Saint Louis Missouri, 63110, United States
Albany New York, 12208, United States
Bronx New York, 10461, United States
Jamaica New York, 11432, United States
New York New York, 10029, United States
Stony Brook New York, 11794, United States
Durham North Carolina, 27701, United States
Cleveland Ohio, 44106, United States
Cleveland Ohio, 44195, United States
Philadelphia Pennsylvania, 19004, United States
Philadelphia Pennsylvania, 19107, United States
Houston Texas, 77054, United States
San Antonio Texas, 78229, United States
Charlottesville Virginia, 22908, United States
Norfolk Virginia, 23502, United States
Turku , FI-20, Finland
Hamburg , 20246, Germany
Munich , 81675, Germany
Nijmegen , 6532, Netherlands
Veldhoven , 5504 , Netherlands
How clear is this clinincal trial information?
